Table 2.
The ERCP score and laboratory results of progressors and non-progressors at the end of follow-up.
| Variables | ΔERCP score ≥2 or dilatation in 3 years |
p value∗ | |
|---|---|---|---|
| No, n = 234 | Yes, n = 164 | ||
| ERCP score | 6 (2–8) | 10 (8–12) | <0.001 |
| Mayo score | -0.51 (-0.92–0.12) | -0.31 (-0.81–0.40) | 0.24 |
| FIB4 | 1.06 (0.75–1.80) | 1.04 (0.69–1.79) | 0.69 |
| AOM | 1.54 (1.19–1.94) | 1.58 (1.20–2.06) | 0.33 |
| B-Hb, g/L | 142 (129–152) | 137 (125–151) | 0.25 |
| B-platelets, 109/L | 256 (210– 313) | 277 (208– 336) | 0.66 |
| P-AST, U/L | 30 (24–43) | 35 (26–57) | 0.081 |
| P-ALT, U/L | 32 (21–56) | 43 (22–73) | 0.13 |
| P-ALP, U/L | 101 (79–145) | 125 (83–210) | 0.025 |
| P-GT, U/L | 48 (21–131) | 77 (32–215) | 0.003 |
| P-Bil, μmol/L | 12 (8–19) | 11 (8–19) | 0.32 |
| P-Alb, g/L | 39.0 (36.0–41.0) | 37.5 (34.8–40.2) | 0.069 |
| P-TT, % | 102 (85–117) | 101 (85–122) | 0.92 |
| P-IgG, g/L | 11.9 (10.3–13.8) | 12.0 (10.3–14.5) | 0.81 |
| S-IgG4, g/L | 0.54 (0.25–1.05) | 0.68 (0.34–1.24) | 0.24 |
| S-IL8, pg/L | 39.7 (21.5–102.0) | 53.1 (23.4–193.4) | 0.19 |
| S-CEA, μg/L | 1.10 (1.00–2.00) | 1.30 (1.00–2.00) | 0.087 |
| S-CA19-9, IU/L | 6.0 (2.0–12.0) | 6.0 (3.0–13.5) | 0.63 |
| Biliary calprotectin, mg/L | 1.3 (0.2–11.8) | 18.7 (1.3–107.5) | <0.001 |
| Biliary IL8, μg/L | 0.94 (0.08–5.74) | 6.42 (0.73–21.98) | <0.001 |
| Dysplasia, n (%) | 11 (5) | 33 (20) | <0.001 |
Data are presented as median (IQR) unless otherwise stated.
∗p values between groups adjusted for baseline value.
Median score and serum levels (bars represent interquartile ratio, IQR or count as percentage). Unadjusted differences between the groups were evaluated using the t test, Mann‒Whitney test, or chi-square test. When adjusting for disease duration between the groups, the non-parametric Koch’s test was used.
For abbreviations, see Table 1 legend.